Induction of Metastasis by S100P in a Rat Mammary Model and Its Association with Poor Survival of Breast Cancer Patients

Guozheng Wang, Angela Platt-Higgins, Joe Carroll, Suzete de Silva Rudland, John Winstanley, Roger Barraclough, and Philip S. Rudland

Cancer and Polio Research Fund Laboratories, School of Biological Sciences, University of Liverpool, Liverpool, United Kingdom

Abstract

S100P, an EF-hand calcium-binding protein, has been reported to be associated with the progression of many types of cancers. Transfection of an expression vector for S100P into a benign, nonmetastatic rat mammary cell line causes a 4- to 6-fold increase in its level in all four transformant cell clones. When the resultant transformant cell lines are introduced in turn into the mammary fat pads of syngeneic Furth-Wistar rats, there is a significant 3-fold increase in local muscle invasion and a significant induction of metastasis in 64% to 75% of tumour-bearing animals. In a group of 303 breast cancer patients followed for up to 20 years, antibodies to S100P immunocytochemically stain 161 primary tumors. Survival of patients with S100P-positive carcinomas is significantly worse by about 7-fold than for those with negatively stained carcinomas. There is also a significant association between the class level of immunocytochemical staining of the carcinoma cells and decreased patient survival. Positive staining for S100P is significantly associated with that for two other metastasis-inducing proteins, S100A4 and osteopontin. Patients with tumors that stained positively for both S100P and S100A4 have a significantly reduced survival of 1.1% over patients with either S100 protein alone. Multivariate regression analysis identifies S100P, S100A4, and osteopontin as the most significant independent indicators of death in this group of patients. These results suggest that stratification of patients into groups according to expression of multiple metastasis-inducing proteins may lead to a more accurate prediction of patient survival. (Cancer Res 2006; 66(2): 1199-207)

Introduction

Members of the S100 family of small regulatory calcium-binding proteins, such as S100A2, S100A4, S100A6, S100A7, S100B, and S100P (1–3), have been reported to be associated with many different types of cancers (4). The best studied, S100A4, has been shown to induce metastasis in rodent mammary model systems for breast cancer and to be associated with poor patient outcomes in breast, colon, non–small-cell lung cancer, and esophageal squamous carcinoma (1–4). It is thought to act primarily by binding to the cytoskeleton and altering cellular motility, although extracellular mechanisms have also been suggested (1–4). The gene for another S100 protein, S100P (5), has recently attracted much attention, because it seems to be a differentially expressed gene in many systematic screenings for their benign counterparts. For example, the gene for S100P is up-regulated in pancreatic cancers (6–9), lung cancer (10), oral squamous cell carcinoma (11), prostatic (12), and breast cancer (13, 14). These observations show a strong association between tumor progression and the elevated expression of S100P. However, it is not clear if the presence of S100P is a causative factor or merely a passenger change in this process. In this study, the metastasis-inducing property of S100P has been investigated in a syngeneic rat model of breast cancer and the association of the presence of S100P in specimens of primary breast carcinomas with the survival of a group of 303 patients with up to 20 years follow-up has been examined using immunocytochemical staining.

Materials and Methods

Plasmid preparation and expression. The S100P coding sequence was amplified from human S100P cDNA by PCR using the following primers: forward 5′-GACAAGCTTATGAGAAGCTGAGACAG and reverse 5′-GGCGATCTCTATTTGATTCGGCCTCTC. The PCR fragment was digested with HindIII and BamHI and subcloned into pCDNA3.1 vector (Invitrogen, Paisley, Scotland) to generate an expression construct, pCDNA-S100P. The identity of the coding sequence for S100P in the pCDNA vector was confirmed by DNA sequencing. Recombinant human S100P (rhS100P) was prepared as previously described (15).

Cell culture and transfection. Rat mammary (Rama) 37, a non–metastatic benign rat mammary tumor-derived cell line (16), expressing undetectable levels of S100P mRNA by Northern and Western blotting, was transfected with pCDNA-S100P or empty pCDNA3.1 as previously described (17). Surviving single-cell colonies were cloned (16) and then grown under selective conditions for 14 days. Two clones expressing high levels of S100P were designated as R37-S100P-1 and R37-S100P-2, whereas the pooled clones, Pool 1 and Pool 2, from two individual transfections were established. Pooled clones from the transfection of pCDNA3.1 expression vector into Rama 37 cells were termed R37 vector.

Northern hybridization. Total RNA was extracted from the single-cell and pooled transfectant cell lines using the guanidinium isothiocyanate–cesium chloride method (18). The separation of RNAs by electrophoresis, blotting, and hybridizations to [32P]dCTP-labeled S100P and β-actin cDNAs were carried out as previously described (17, 19). The bands were quantified using Quantity One software in a Bio-Rad ChemiDoc analyser (Hemel Hempstead, Hertfordshire, United Kingdom).

Western blotting. Fifty micrograms of cell lysates from cultured cells (17) and fresh-frozen specimens of human breast cancers (20), prepared as previously described, were separated on SDS-PAGE gels and then electrophoretically transferred onto Immobilon P membranes (Millipore, Watford, United Kingdom). The membranes were probed with mouse monoclonal antibody to human S100P (BD Sciences, Cowley, United Kingdom) diluted 1:50 and with polyclonal antibody to S100A4 (DakoCytomation, Glostorp, Denmark) diluted 1:1,000 (17, 21). In some experiments, 100 μg/mL rhS100P or rhS100A4 was preincubated with the mAb to human S100P for 2 hours at room temperature as a blocked antibody control. The bands were visualized using horseradish peroxidase–conjugated secondary antibody and enhanced chemiluminescence (Pierce Biotechnology, Inc., Perbio Science, Framlington, Northumberland, United Kingdom)

Requests for reprints: Philip S. Rudland, School of Biological Sciences, Bioscience Building, University of Liverpool, Liverpool L69 3BX, United Kingdom. Phone: 44-151-795-4474; Fax: 44-151-795-4406; E-mail: wangg@liv.ac.uk.

© 2006 American Association for Cancer Research. doi:10.1158/0008-5472.CAN-05-2605
**Tumorigenicity and metastasis.** Metastasis assays of transfected cells were done by injecting 2 × 10^6 cultured cells s.c. into the mammary fat pad region of syngeneic female Furth-Wistar rats. The histology of tumors and tissues isolated at autopsy after 2 to 3 months was carried out as previously described (16, 22). At least two sections of each tumor/tissue were examined by two independent observers. Animals containing microscopically visible metastases of malignant cells in the lungs and blocks of striated muscle infiltrated by malignant cells at the periphery of the primary tumors were scored positive for metastasis and invasion, respectively. Immunocytochemical staining for S100A4, myoglobin, and general keratins was as previously described (17, 23) and that for S100P was recorded below.

**Histologic sections of 3- to 4-μm thickness prepared from paraffin-embedded sections were dewaxed and immunocytochemically stained using 1:50 diluted mAb to S100P (BD Sciences) and Envision+ system kit (DakoCytomation) according to the instructions of the supplier. Blocked antibody was prepared by mixing mAb to S100P with 100 μg/mL recombinant glutathione S-transferase (GST)-S100P fusion protein or with 100 μg/mL rhS100P. Slides from all 303 of the specimens stained by the mAb to hS100P were analyzed independently by two observers using light microscopy. The percentage of stained carcinoma cells was recorded from two sections of each specimen, 10 fields per section at ×200 magnification. Staining for S100P was evaluated in five classes: negative (−), <1%; borderline (±), 1% to 5%; intermediate (+), 5% to 25%; moderate (++), 25% to 50%; and strong (+++), >50% of the carcinoma cells stained, so as to divide the population into roughly equally sized groups, as previously described for the staining of osteopontin (24).

**Statistical methods.** The association of S100P with tumor cell invasion and metastasis in the rat model and that of immunocytochemical staining for S100P in human breast cancer specimens with other tumor variables (20) was assessed using Fisher’s exact test; two-sided values of probability (P) are given (26). The cutoff value between those groups of patients designated negatively or positively immunocytochemically stained for the marker proteins was usually set at 5% unless otherwise specified (20, 24, 27, 28). The association of staining for S100P in breast cancers with patient survival was evaluated using life tables constructed from survival data.
data with Kaplan-Meier plots and analyzed using generalized Wilcoxon (Gehan) statistics (26). Those patients who died of causes other than cancer were treated as censored observations (27). To assess unadjusted relative risk (RR) for survival and 95% confidence interval (95% CI), a Cox univariate analysis was done as before (26). To determine whether the association of patient survival with S100P was independent of other prognostic factors, a multivariate analysis was done using Cox’s proportional hazards model on 136 patients with full data sets (29). Data processing and statistical analyses were done using Excel version 97 (Microsoft Corp., Redmond, WA) and Statistical Package for the Social Sciences version 10.0 (SPSS, Inc., Chicago, IL).

Results

Generation of S100P-overexpressing rat mammary cell lines. The parental Rama 37 cells used for transfection and R37-vector alone cells contained virtually undetectable levels of mRNA and protein for S100P using Northern and Western blotting, respectively (Fig. 1A). The Rama 37 cells transfected with the expression vector pCDNA-S100P (R37-S100P-1, R37-S100P-2, Pool 1, and Pool 2) produced an average (±SD) of 10 ± 3.4-fold higher levels of S100P mRNA (0.6 kbp) and 5 ± 1.2-fold higher levels of the S100P protein (10 kDa) than that of R37 vector control (Fig. 1A). No S100A3 mRNA or protein was detected in the R37-vector– or pCDNA-S100P–transfected cell lines (Fig. 1B). In controls, prior incubation of the mAb with rhS100P, but not with rhS100A4, completely abolished the 10-kDa band in the Western blots of the transfectants (Fig. 1B).

Effect of S100P overexpression on invasive and metastasizing ability in rats. S.c. injection into the mammary fat pad region of female Furth-Wistar rats with the transfected cell lines yielded primary tumors in 64% to 80% of the animals; no statistically significant differences were observed between any of these cell lines (Table 1). All transfected cell lines produced tumors with some degree of invasion in the underlying muscle, but all four cell lines overexpressing S100P produced significantly higher (70-87%) muscle invasive tumors (Fig. 2A) than that of the 28% due to R37-vector cells (Fisher’s exact test, P ≤ 0.01). Metastases were also observed, but to a lesser extent, in the axillary lymph nodes draining the primary tumor produced by pCDNA-S100P transfectants.

On histologic examination, some metastases in the lungs were smaller, more diffuse, and surrounded by blood vessels (Fig. 2B); others were large cannon ball metastases >5 mm in diameter (Fig. 2C). Immunocytochemical staining for S100P confirmed that S100P was overexpressed in those tumors/metastases that were produced by the pCDNA-S100P transfectants (Fig. 2C and D), but not in the primary tumors/lungs of the rats injected with R37-vector cells (not shown). The mAb to S100P stained both the nuclei and the cytoplasm of the tumor cells (Fig. 2D) and this staining was completely abolished by prior incubation of the mAb with rGST-S100P (Fig. 2E).

Immunocytochemical staining for general keratins confirmed the epithelial nature of the glandlike elements in both the primary tumors and metastases (not shown). On inspection of histologic sections, the numbers of peripheral blood vessels adjacent to the invasive edge of the primary tumors were not appreciably different for any of the transfectant cell lines, including the R37-vector cells, nor were these vessels stained for S100P although large numbers of infiltrating lymphocytes were stained intensely (Fig. 2F).

Immunocytochemical staining of human breast carcinomas for S100P. Immunocytochemical staining of normal human parenchymal breast tissues was, with the exception of ductal hyperplasias and carcinoma in situ, relatively unstained (not shown), whereas that of breast carcinomas ranged from none (Fig. 3A) to >90% of carcinoma cells staining (Fig. 3B and C). Of the 303 invasive breast carcinomas evaluated, 62 (20.5%) were classified as unstained (−; <1% of carcinoma cells stained; Fig. 3A); 80 (26.4%) were borderline stained (±; 1-5% carcinoma cells stained; Fig. 3B), and the remaining 161 (53.1%) were stained to some degree by the mAb to S100P. These were further subdivided into classes of 60 (19.8%) moderate (+; 5-25% cells stained), 53 (17.5%) strong (++; 25-50% cells stained), and 48 (15.8%) very strong (>50% of

**Table 1. Incidence of tumors, muscle invasion, and metastasis by transfected cell lines**

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>S100P</th>
<th>Tumor incidence, n (%)</th>
<th>Invasion of muscle, n (%)</th>
<th>Incidence of metastasis, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>R37-vector</td>
<td>−</td>
<td>27 of 38 (71)</td>
<td>5 of 18 (28)</td>
<td>0 of 27 (0)</td>
</tr>
<tr>
<td>R37-S100P-1</td>
<td>+</td>
<td>18 of 25 (72)</td>
<td>7 of 10 (70)</td>
<td>13 of 18 (72)</td>
</tr>
<tr>
<td>R37-S100P-2</td>
<td>+</td>
<td>20 of 25 (80)</td>
<td>13 of 15 (87)</td>
<td>14 of 20 (70)</td>
</tr>
<tr>
<td>Pool 1</td>
<td>+</td>
<td>14 of 22 (64)</td>
<td>5 of 7 (71)</td>
<td>9 of 14 (64)</td>
</tr>
<tr>
<td>Pool 2</td>
<td>+</td>
<td>8 of 12 (67)</td>
<td>4 of 5 (80)</td>
<td>6 of 8 (75)</td>
</tr>
</tbody>
</table>

*Number of tumors/number of animals inoculated. Tumor incidence of the S100P transfected cells was not significantly different from that of the R37-vector cells (Fisher’s exact test, P ≥ 0.21).

Numbers of animals with muscle invasion/numbers of animals with tumors adjacent to muscle. Animals that contained no visible muscle blocks were eliminated from the analysis. No significant differences were found in the incidence of muscle invasion among two R37-S100P clones and two Pools (P ≥ 0.31) of transfectants, but the incidences of these four cell lines were significantly higher than that of R37-vector cells (P ≤ 0.045).

Numbers of animals with lung metastases/number of animals with tumors. There were no significant differences in the incidence of metastasis among the two separate clones of R37-S100P and two Pools (P ≥ 0.60), but the incidences of metastasis of R37-S100P-1/-2 or Pool 1/2 were significantly higher than that of R37-vector cells (P ≤ 0.01).
carcinoma cells stained) staining carcinomas (Fig. 3C). For most analyses, the borderline staining carcinomas were combined with the unstained carcinomas into one group of negatively stained carcinomas, leaving the clearly positive staining carcinomas as the other categorical group. There was a good degree of consistency between the two observers with agreement in 94.8% of cases corresponding to a $\kappa$ score of 0.92. Intratumor heterogeneity was higher than this at 6.9% for two well-separated sections of the same tumor. In the latter cases, additional sections were immunocytochemically stained and analyzed to obtain a consensus result.

The immunocytochemical staining for S100P was predominantly nuclear with some cytoplasmic staining (Fig. 3C) and was abolished by prior incubation of the mAb with rGST-S100P (Fig. 3D). In positive staining carcinomas, the mAb failed to stain the majority of blood vessels adjacent to the invasive edge of the tumor (Fig. 3E). However, when this mAb was preincubated with rhS100P lacking the GST fusion protein, staining of the cytoplasm, membrane, and extracellular matrix of the carcinoma cells and that of the same peripheral blood vessels dramatically increased (Fig. 3F). This was particularly evident at higher microscopic power (Fig. 3G and H). Preincubation of the mAb to S100P with rhS100A1 produced no such change (not shown).

When tested in Western blots of extracts from immunocytochemically positive breast carcinomas, the mAb to S100P detected two bands: a major of 10 kDa and a minor of 20 kDa apparent molecular weight (Fig. 1C), which corresponded in size to that of monomers and dimers of authentic rhS100P (Fig. 1C). Their appearance was abolished by prior incubation of the mAb with rhS100P (Fig. 1C) but not with rhS100A4 (not shown). The appearance of the dimer may be due to the preparation procedures of the human sample (20). In seven samples chosen at random, there was a significant correlation between the level of immunodetectable...
S100P by Western blotting and the percentage of cells immunocytochemically stained for S100P ($r^2 = 0.96$, $P = 0.01$; Fig. 1D).

**Association of S100P with other tumor variables.** The presence of definitely positive immunocytochemical staining for S100P was cross-tabulated with other tumor variables associated with outcome in this group of patients (20, 24); these included tumor size, histologic grade, nodal status, and the immunocytochemical presence of S100A4, osteopontin, c-ERBB-2, c-ERBB-3, cathepsin D, p53, estrogen receptor $\alpha$, progesterone receptor, and pS2 (Table 2). The cutoff levels of all tumor variables were set at 5% of the carcinoma cells stained and statistical significance was assessed using Fisher’s exact test. A significant association of staining for S100P was observed with five of the prognostic markers including S100A4 ($P < 0.0001$), osteopontin ($P < 0.0001$), c-ERBB-3 ($P < 0.0001$), cathepsin D ($P = 0.001$), and pS2 ($P = 0.026$). Carcinomas in the axillary lymph nodes showed a borderline association with immunocytochemical staining for S100P in the primary tumor ($P = 0.060$; Table 2). If the cutoff levels were set at 1% for S100P and 5% for the other immunocytochemically detected tumor variables, a significant association of staining for S100P was found with that for S100A4 ($P < 0.0001$), osteopontin ($P < 0.0001$), c-ERBB-3 ($P = 0.031$), p53 ($P = 0.028$), and carcinoma in axillary lymph nodes ($P = 0.012$; data not shown).

**Association of S100P and patient survival.** The association of immunocytochemical staining for S100P and the cumulative proportion of patients surviving at yearly intervals after the time of presentation are shown in Fig. 4. Patients were divided into two classes using a 5% cutoff: S100P(−) with <5% carcinoma cells stained and S100P(+) with >5% carcinoma cells stained. Of the 142 patients who were classified as S100P(−), 82.5% were alive at the census date with a median survival time of >216 months, in comparison with 16.9% of the 161 patients classified as S100P(+).
with a median survival time of 59.4 months. Over the full follow-up period of 20 years, the survival of patients with S100P-positive carcinomas was highly significantly worse than those patients with carcinomas classified as S100P-negative (Wilcoxon test, P < 0.0001) with RR of increased death from cancer of 7.3 (95% CI, 4.7-11.5; Fig. 4B). These differences became significant after 2 years of follow-up. If the cutoff levels were set at 1% instead of 5% of the carcinoma cells staining for S100P, the two groups with carcinomas was highly significantly worse than those patients with different classes of positively staining tumors (P = 0.67; Fig. 4B). These progressive decreases in survival corresponded to progressive increases in RR of demise from breast cancer between the negative (−)/borderline (+), the borderline (±)/moderate (+), and the moderate (+)/strong (+++) staining groups of 10.3 (95% CI, 2.4-44), 3.6 (95% CI, 2.1-6.1), and 1.3 (95% CI, 0.8-2.1) respectively, yielding an overall difference in RR of 47 (95% CI, 11-200) between the negative (−) and strong (+++) or very strong (++++) staining groups.

### Table 2. Association of staining for S100P with other tumor variables

<table>
<thead>
<tr>
<th>Tumor variables*</th>
<th>S100P negative, n (%)</th>
<th>S100P positive, P†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymph node—</td>
<td>64 (59.3)</td>
<td>53 (46.1)</td>
</tr>
<tr>
<td>Lymph node+</td>
<td>44 (40.7)</td>
<td>62 (53.9)</td>
</tr>
<tr>
<td>Grade 1, 2</td>
<td>96 (78.7)</td>
<td>109 (74.1)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>26 (21.3)</td>
<td>38 (25.9)</td>
</tr>
<tr>
<td>Tumor size 1, 2</td>
<td>103 (75.7)</td>
<td>119 (76.3)</td>
</tr>
<tr>
<td>Tumor size 3, 4</td>
<td>33 (24.3)</td>
<td>37 (23.7)</td>
</tr>
<tr>
<td>Osteopontin—</td>
<td>85 (59.9)</td>
<td>20 (12.9)</td>
</tr>
<tr>
<td>Osteopontin+</td>
<td>57 (40.1)</td>
<td>135 (87.1)</td>
</tr>
<tr>
<td>Estrogen receptor α—</td>
<td>67 (46.9)</td>
<td>78 (50)</td>
</tr>
<tr>
<td>Estrogen receptor α+</td>
<td>76 (53.1)</td>
<td>78 (50)</td>
</tr>
<tr>
<td>C-ERBB-2—</td>
<td>78 (54.9)</td>
<td>44 (28.4)</td>
</tr>
<tr>
<td>C-ERBB-2+</td>
<td>64 (45.1)</td>
<td>111 (71.6)</td>
</tr>
<tr>
<td>C-ERBB-3—</td>
<td>78 (44.8)</td>
<td>30 (20.9)</td>
</tr>
<tr>
<td>C-ERBB-3+</td>
<td>64 (45.1)</td>
<td>111 (71.6)</td>
</tr>
<tr>
<td>S100A4—</td>
<td>125 (85)</td>
<td>64 (40)</td>
</tr>
<tr>
<td>S100A4+</td>
<td>22 (15)</td>
<td>96 (60)</td>
</tr>
<tr>
<td>Progesterone receptor—</td>
<td>92 (66.2)</td>
<td>87 (56.9)</td>
</tr>
<tr>
<td>Progesterone receptor+</td>
<td>47 (33.8)</td>
<td>66 (43.1)</td>
</tr>
<tr>
<td>p53—</td>
<td>98 (67.1)</td>
<td>92 (57.9)</td>
</tr>
<tr>
<td>p53+</td>
<td>48 (32.9)</td>
<td>67 (42.1)</td>
</tr>
<tr>
<td>Cathepsin D—</td>
<td>59 (33.2)</td>
<td>38 (20.4)</td>
</tr>
<tr>
<td>Cathepsin D+</td>
<td>52 (46.8)</td>
<td>87 (69.6)</td>
</tr>
<tr>
<td>p52—</td>
<td>97 (66.4)</td>
<td>84 (53.5)</td>
</tr>
<tr>
<td>p52+</td>
<td>49 (33.6)</td>
<td>73 (46.5)</td>
</tr>
</tbody>
</table>

*Lymph node with tumor (+) or without tumor (−): grade, histologic grade 3 versus histologic grades 1, 2; tumor sizes >5 cm or fixed to the chest wall (sizes 3,4) versus tumor <5 cm in diameter (sizes 1, 2); for the rest of the tumor variables, the presence (+) or absence (−) of immunocytochemical staining using a cutoff of 5% of the carcinoma cells stained.

†Number of patients with carcinomas either classified as staining (+, positive) or not staining (−, negative) for S100P. Parentheses show the percentage of patients.

‡Probability between paired samples from Fisher’s exact test (two-sided value).
with patient survival (residual $\chi^2 = 11.4, 9 \text{ df}, P = 0.25$). As soon as S100P emerged in the first step of the analysis, the independent significance of association of tumor involved lymph nodes with patient survival was lost ($\chi^2 = 1.83, 1 \text{ df}, P = 0.18$).

**Discussion**

Transfection of S100P cDNA in an expression vector into the benign rat mammary cell line, Rama 37, produces a protein consistent with the size of S100P (5) in two independent single-cell clones and two clone pools. All four transfectants induce metastases in vivo whereas similar transfectant with the vector alone failed to induce any metastases as before (17, 30–32). The use of pooled clones and two single-cell cloned cell lines overexpressing S100P eliminates the possibility of spontaneous induction of metastasis in the benign Rama 37 cell line (33). The fact that the primary tumors and lung/lymph node metastases produced by the four S100P cDNA transfectants possess the same histology, including the giant polynucleated cells, and can be immunocytochemically stained for S100P, whereas the primary tumors produced by the vector-alone transfectants are not, strongly suggests that the metastases develop as a result of the expression of S100P. Moreover, overexpression of the closely related metastasis-inducing S100A4 (22) is not detected in the S100P cDNA transfectants, either in culture or in metastatic lesions in vivo, thus eliminating the possibility that the metastases are due to the presence of endogenous S100A4. Although S100P has been shown to occur preferentially in malignant as opposed to nonmalignant disease (13, 34), particularly that of the pancreas (6, 7), this is the first formal demonstration that S100P can directly induce metastasis in vivo. The appearance of the lung metastases as diffuse, often surrounding blood vessels and as cannon balls is consistent with lymphatic and blood born spread, respectively (35).

The potential clinical relevance of the overexpression of S100P has been sought using immunocytochemistry on primary tumors of a group of 303 breast cancer patients with follow-up of up to 20 years. In agreement with others, there is little staining of normal glandular tissue (6, 7, 13). There is, however, a heterogeneous staining pattern for the primary tumor, consistent with that observed in other studies with very much smaller numbers of patients (6, 13). When the tumor variables which show a significant association with outcome in this group of breast cancer patients are tested for association with immunocytochemical staining for S100P in the primary carcinomas, staining for the metastasis-inducing proteins S100A4 (22) and osteopontin (30) is the most significantly associated at both the 5% and 1% cutoff levels for staining for S100P. These results may suggest that the same

---

**Figure 4.** Association of immunocytochemical staining for S100P with overall survival of patients. **A,** the cumulative proportion of surviving patients as a fraction of the total classified as follows: —, completely negative staining (100% = 62 patients; a); ±, borderline staining (100% = 80 patients; b); +, moderate staining (100% = 60 patients; c); ++, strong staining (100% = 53 patients; d); and ++++, very strong staining (100% = 48 patients; e) for S100P. There were 60 censored observations in a (10 dead of other causes); 58 in b (12 dead of other causes); 23 in c (14 dead of other causes); 13 in d (10 dead of other causes); and 12 in e (8 dead of other causes). The two curves are highly significantly different (Wilcoxon statistics $\chi^2 = 73.3, 1 \text{ df}, P < 0.0001$). **B,** the cumulative proportion of surviving patients as a fraction of the total classified as follows: $\chi^2 = 82.72, 4 \text{ df}, P < 0.0001$ and significantly different in the successive pairwise combinations for a with b ($\chi^2 = 14.62, 1 \text{ df}, P = 0.0001$) and with c ($\chi^2 = 14.16, 1 \text{ df}, P = 0.0002$), but not for c with d ($\chi^2 = 0.18, 1 \text{ df}, P = 0.67$) nor d with e ($\chi^2 = 0.01, 1 \text{ df}, P = 0.91$). **C,** the cumulative proportion of surviving patients as a fraction of the total classified as S100P(−)/S100A4A1(−) staining (100% = 120 patients; a); S100P(−)/S100A4A1(+) staining (100% = 64; b); S100P(+)S100A4A1(−) staining (100% = 22 patients; c); and S100P(+)S100A4A1(+) staining (100% = 96 patients; d). There were 109 censored observations in a (19 dead of other causes); 40 in b (22 dead of other causes); 9 in c (5 dead of other causes); and 7 in d (5 dead of other causes). The curves are highly significantly different (Wilcoxon statistics $\chi^2 = 129.7, 3 \text{ df}, P < 0.0001$) and significantly different in the successive pairwise combinations for a with b ($\chi^2 = 20.5, 1 \text{ df}; P < 0.0001$), b with c ($\chi^2 = 34.9, 1 \text{ df}; P < 0.0001$), and c with d ($\chi^2 = 34.1, 1 \text{ df}; P = 0.0065$), but not for b with c ($\chi^2 = 2.9, 1 \text{ df}, P = 0.088$).
underlying change(s) is responsible for the altered expression of these three metastasis-inducing proteins. One other consistent association of S100P with a tumor variable is that with carcinoma in the lymph nodes; this association is of borderline significance at 5% (Fisher exact test, \( P = 0.06 \)) and significant at 1% cutoff levels (\( P = 0.012 \)) of carcinoma cells staining for S100P. Because the nodal status has been recorded for only 74% of the tumors in this study, this smaller number may render the tests for its positive association with S100P less significant than it may otherwise have been.

The overall survival for patients with carcinomas stained positively for S100P is shown to be highly significantly worse than for patients with carcinomas classified as negatively stained (Wilcoxon statistics \( \chi^2 = 73.3, P < 0.0001 \)) and comparable to that for the other two metastasis-inducing proteins, S100A4 (\( \chi^2 = 131.5, P < 0.0001; \) ref. 20) and osteopontin (\( \chi^2 = 95.4, P < 0.0001; \) ref. 24), as well as with involved lymph nodes (\( \chi^2 = 17.3, P < 0.0001; \) ref. 20). The RR of death of patients with S100P positive tumors is 7.3 (95% CI, 4.5-11.5) in this group of patients, smaller than that for S100A4 of 8.7 (95% CI, 6.7-12.7; ref. 20) and osteopontin of 21.5 (95% CI, 9.5-48.9; ref. 24), but still considerably higher than that for involved lymph nodes of 2.1 (95% CI, 1.4-3.0; ref. 20). This relationship for S100P achieved statistical significant after 2 years compared with that for S100A4 after 6 months and for osteopontin after 1 year of follow-up. The fact that comparable results are obtained for S100P at the 1% (not shown) as well as the 5% cutoff level means that their significance is not dependent on one arbitrary cutoff level dividing the negative and positively staining groups of tumors. Grouping the patients into classes according to the % carcinoma cells staining for S100P shows that not only the presence but also the proportion of carcinoma cells staining for S100P up to a limit of 25% is correlated with the time of death of the patients. This result suggests that the levels of immunoreactive S100P may be correlated with their time of death. The fact that the presence of immunoreactive S100P is so closely correlated with early death in this group of patients may suggest that this change, like that of S100A4 and osteopontin, is closely associated with its cause, possibly by its ability to induce metastasis in humans.

Although both S100P and S100A4 can independently induce metastasis in the same rat mammary cell system and both are associated with poor outcomes of breast cancer patients, there are some obvious differences. First, immunocytochemical staining of the carcinoma cells in human breast cancers localizes S100P predominantly to the nucleus with a weak staining in the cytoplasm, like S100A2 (36) and S100A6 (37). In contrast, S100A4 (37) occurs predominantly in the cytoplasm and extracellularly, like S100B (38), particularly in endothelial cells in vessels adjacent to stained carcinomatous areas. Moreover, when serial adjacent sections are incubated with rhS100P complexed with mAb to S100P, staining in the cytoplasm and extracellular matrix, particularly that of the endothelial cells, is enhanced in the rat and human tumors (Fig. 3E-H). The staining pattern is now similar to that for antibodies to S100A4. However, blocking controls of the mAb to S100P with the fusion protein GST-S100P abolish all staining of histologic sections of S100P-positive tumors (Figs. 2E and 3D) and this inhibition is not due to simple interference by GST of the binding of the S100P mAb (data not shown). The more likely explanation is that there are potential receptors for S100P in the cytoplasm/extracellular matrix/endothelial cells which are unoccupied and antibody-bound S100P can locate them, as previously described for fibroblast growth factor 2 (39). The GST protein fused at the NH2 terminus of S100P may disturb a potential binding site on S100P for its binding partners, thereby abolishing staining completely. These conclusions are consistent with an extracellular role for S100A4 in stimulating tumor angiogenesis (40, 41), which would seem to be largely absent in the case of S100P in human breast cancer.

When these tumor variables which are associated with patient outcome are assessed in the Cox proportional hazards model, immunocytochemical stainings for all three metastasis-inducing proteins together with involved lymph nodes and estrogen receptor \( \alpha \) emerge as significant independent prognostic indicators. The fact that large tumor size, high histologic grade, and staining for c-ERBB-2, c-ERBB-3, p53, progesterone receptor, p52, and cathepsin D are rejected as independent prognostic factors in the Cox multivariate analysis may suggest that they are confounded by one or more of the independent prognostic variables in the proportional hazards model. When the results for two of the metastasis-inducing proteins are left out in turn, the remaining metastasis-inducing protein emerges as the most significant: S100A4, \( P < 0.0001 \); RR = 7.5 (20); osteopontin, \( P < 0.0001 \), RR = 12.9 (24); and S100P, \( P < 0.001 \), RR = 4.7. As soon as S100P emerges in the first step of the analysis as the most significant tumor variable, the independent significance of the association of tumor-involved lymph nodes is lost. This result is in contrast to that for S100A4 and osteopontin in which involved lymph nodes remain significantly associated with patient survival after the final analysis. These results suggest that of the three metastasis-inducing proteins, the one most closely associated with involved lymph nodes is S100P in relation to patient survival. When all the data are combined, the order the tumor variables emerge is in agreement with the results of subgroups of patients with tumors staining for S100P and/or S100A4 or S100P and/or osteopontin. Moreover, patients with S100A4(+)/S100P(+) tumors (Fig. 4C) or osteopontin (+)/S100P(+) tumors (not shown) are likely to die significantly earlier than patients with S100A4(+)/S100P(−) or osteopontin (+)/S100P(−) tumors, the RR being 2.6 (95% CI, 1.4-4.7) and 3.3 (95% CI, 2.1-5.3), respectively. The RR for patients with S100A4(+)/S100P(+) tumors compared with those with S100A4(−)/S100P(−) tumors at 26 (95% CI, 13-49) and the RR for patients with osteopontin(+) or S100P(+) tumors compared with those with osteopontin(−) or S100P(−) tumors at 143 (95% CI, 20-1030) are both extremely high. These results show that the use of multiple metastasis-inducing proteins can pinpoint subgroups of patients that are likely to do well or badly much more accurately than those with either one metastasis-inducing protein alone or with the expression profile of 70 selected genes in array analyses (42). Moreover, in the case of S100P and S100A4, two structurally similar molecules (15, 43), stratification of patients into one group opens the way in the future to target this group with the same medicinal compound active against both metastasis-inducing proteins.

**Acknowledgments**

Received 7/25/2005; revised 10/20/2005; accepted 10/26/2005.

**Grant support:** Cancer and Polio Research Fund.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank C. Holcombe and the Breast Unit, Royal Liverpool University Hospital, for clinical assistance; Dr. E.M.L. Williams and the staff of the Merseyside and Cheshire Cancer Registry for providing patient outcome data; and Barry Cottrell and Karen Collard for excellent technical assistance.

---

1 de Silva Rudland et al., Clinical Cancer Research, submitted for publication.
References

Induction of Metastasis by S100P in a Rat Mammary Model and Its Association with Poor Survival of Breast Cancer Patients
